Brussels, Belgium — As geopolitical tensions escalate, health ministers from 11 European Union member states have issued a stark warning about the continent’s overreliance on Asia for critical medicines.
In an exclusive article for Euronews, the ministers emphasized that treating medicine security as a secondary issue would be a grave miscalculation, potentially turning this dependency into the Achilles’ heel of Europe’s security.
With 80–90% of the world’s antibiotics produced in Asia — predominantly in China — Europe’s healthcare systems are exposed to significant risk.
The COVID-19 pandemic already highlighted the vulnerabilities in the pharmaceutical supply chain, causing severe shortages of essential medicines across Europe.
However, the ministers warn that in the event of an escalating conflict, such dependencies could have even more catastrophic consequences.
Dependence on Asia: A Critical Vulnerability
Once a leader in pharmaceutical production, Europe now relies on Asia for 60–80% of its medicines, a shift driven by cost pressures and higher labour and environmental standards within the EU.
The ministers argue that this dependence has left the continent exposed to potential supply chain disruptions that could cripple healthcare systems.
“Imagine, for example, that the supply chain of antibiotics is interrupted in the midst of an escalating conflict,” the ministers wrote. “Without these essential medicines, routine surgeries become high-risk procedures, and easily treatable infections could turn fatal.”
Such a scenario, they caution, is not far-fetched. The ongoing geopolitical instability has underscored the strategic importance of medicine security as a core component of national defense and public health infrastructure.
The Critical Medicines Act: A Strategic Response
In response to these concerns, the European Union is set to unveil the Critical Medicines Act this week. Initially proposed in May 2023, the Act aims to map vulnerabilities in the pharmaceutical supply chain, bolster domestic production, and diversify sourcing to reduce reliance on Asian manufacturers.
Key provisions of the Act include:
- Supply Chain Mapping: Comprehensive analysis of critical medicine supply chains to identify weaknesses.
- Support for European Production: Financial and regulatory incentives to ramp up domestic manufacturing of essential medicines.
- Sustainability and Security Criteria: Procurement guidelines that reward sustainable and secure production practices.
The ministers advocate for embedding part of the funding for this Act into broader EU defense spending plans, arguing that without essential medicines, Europe’s defense capabilities could be severely compromised.
A Fragmented Approach to Stockpiling
Another critical issue highlighted by the ministers is the lack of a unified European strategy for stockpiling essential medicines. Currently, stockpiling practices vary widely between member states, leading to significant disparities in preparedness.
The ministers call for a coordinated European approach based on transparency, cooperation, and solidarity to ensure that essential medicines are readily available when needed.
Learning from the United States: A Strategic Model
The ministers urge the European Commission to adopt a strategy similar to the United States’ Defense Production Act (DPA), which designates pharmaceutical supply chains as a national security issue.
The DPA empowers the U.S. government to map critical supply chains, identify vulnerabilities, and direct investments to strengthen domestic production capacity.
The DPA also allows the issuance of priority-rated contracts, compelling suppliers to prioritize government orders for essential medicines during crises.
A comparable mechanism in Europe could prevent supply chain disruptions from escalating into full-blown health emergencies.
The COVID-19 Wake-Up Call
The pandemic’s impact on Europe’s medicine supply chain was a stark reminder of the risks posed by overreliance on foreign manufacturers.
Hospitals across the continent faced critical shortages of medicines such as muscle relaxants for emergency intubation and anesthetics for surgical procedures.
Even today, medicine shortages persist across Europe, largely due to the fragility of supply chains dependent on just-in-time deliveries and long, complex value chains.
The ministers argue that Europe cannot afford to treat these shortages as isolated incidents but must recognize them as symptoms of a deeper structural vulnerability.
Strategic Autonomy: A New Security Paradigm
The ministers’ call to action aligns with a broader push within the EU to achieve “strategic autonomy” — reducing dependence on non-European suppliers for critical goods, from semiconductors to energy resources.
Expanding the Critical Medicines Act into a full-scale strategic program, backed by EU defense funding, is seen as a crucial step in this direction.
This approach reflects a growing recognition that health security is an integral component of national security.
As such, the ministers argue, medicine security should be embedded into Europe’s broader security framework, ensuring that the continent can respond swiftly and decisively to potential crises.
A Cross-Border Challenge Demands a Unified Response
The ministers emphasize that no single EU member state can tackle this issue alone. A coordinated response is essential to ensure that critical medicines are available across the continent during emergencies.
They call for enhanced cooperation among member states, not only in terms of stockpiling but also in coordinating procurement and production strategies to prevent supply chain disruptions.
“Health can’t be treated as a secondary issue,” the ministers stress. “The Critical Medicines Act must act as a robust instrument to secure Europe’s strategic autonomy.”
Conclusion: A Turning Point for Europe’s Medicine Security
As the EU prepares to unveil the Critical Medicines Act, the ministers’ message is clear: Europe must act swiftly and decisively to fortify its medicine security.
Failure to do so, they warn, could leave the continent dangerously exposed to both geopolitical threats and future health crises.
By integrating medicine security into its broader defense strategy, the EU has an opportunity to transform a critical vulnerability into a cornerstone of its strategic autonomy.
The upcoming release of the Critical Medicines Act will be a crucial test of Europe’s ability to rise to this challenge.